Simpson E Rand
Ocular Oncology Service, Princess Margaret Hospital/ University Health Network, Toronto, Ont.
Can J Ophthalmol. 2004 Jun;39(4):365-71. doi: 10.1016/s0008-4182(04)80007-3.
Although there is little doubt that the delayed recognition of ciliary body melanoma has a bearing on patient management and ultimate survival, the most compelling issues that face the clinician treating this neoplasm relate to the metastatic patterns and mechanisms of the disease. Several aspects of diagnosis and management of this tumour provide a unique challenge to the clinician. Ciliary body melanoma can remain clinically inapparent to the patient as well as to the clinician during its formative period. In management, tumour characteristics, including anterior and posterior margins, are more readily visualized with ultrasound biomicroscopy (UBM) than with other imaging techniques. UBM can provide valuable information when considering intervention, including biopsy, resection or plaque radiotherapy. Management depends on tumour size, intraocular involvement, patient preference and the presence or absence of systemic manifestations.
尽管睫状体黑色素瘤的延迟诊断无疑会影响患者的治疗和最终生存,但治疗这种肿瘤的临床医生面临的最紧迫问题与该疾病的转移模式和机制有关。该肿瘤诊断和治疗的几个方面给临床医生带来了独特的挑战。在其形成期,睫状体黑色素瘤在临床上可能对患者和临床医生都不明显。在治疗方面,与其他成像技术相比,超声生物显微镜(UBM)能更清晰地显示肿瘤特征,包括前后边缘。在考虑进行活检、切除或敷贴放疗等干预措施时,UBM能提供有价值的信息。治疗取决于肿瘤大小、眼内受累情况、患者偏好以及是否存在全身表现。